Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 18/20 | 0.60 |
| ▸ | SMARCA2 | P51531 | 4/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 4/20 | 0.45 |
| ▸ | ELOC | Q15369 | 5/20 | 0.41 |
| ▸ | ELOB | Q15370 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21456404 | 1.00 | VHL (0.60) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL27164774 | 0.95 | VHL (0.54) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL27164771 | 0.95 | VHL (0.54) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL34469717 | 0.92 | VHL (0.61) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL21456423 | 0.91 | VHL (0.49) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL21456393 | 0.91 | VHL (0.64) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL21456410 | 0.90 | VHL (0.60) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL23205572 | 0.90 | VHL (0.60) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL23205220 | 0.90 | VHL (0.59) | VHLSMARCA2SMARCA4ELOCELOB | |
| SCHEMBL30312575 | 0.89 | VHL (0.60) | VHLSMARCA2SMARCA4ELOCELOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2021067606-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | VHL 3738/4885SMARCA2 731/4885SMARCA4 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.